Volume 11.47 | Dec 6

Cell Therapy News 11.47, December 6, 2010.
In this issue:  Science  |  Policy  |  Business  |  NIH  |  CBER  |  Regulatory  |  Events Subscribe  


Biologists Find That Restoring the Gene for Cancer Protein p53 Slows Spread of Advanced Tumors 
In a new study, cancer biologists show that restoring the protein p53’s function in mice with lung cancer has no effect early in tumor development, but restoring the function later on could prevent more advanced tumors from spreading throughout the body. [Press release from Massachusetts Institute of Technology discussing online prepublication in Nature]



Interested in recruiting talented individuals? Post your career opportunities in Cell Therapy News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @CellTherapyNews


Scientists Map Changes in Genetic Networks Caused By DNA Damage
Using a new technology called “differential epistasis maps,” an international team of scientists has documented for the first time how a cellular genetic network completely rewires itself in response to stress by DNA-damaging agents. [Press release from the University of California, San Diego discussing online prepublication in Science]
Fitting a Biological Nanopore into a Man-Made One, New Ways to Analyze DNA
Researchers announce a new type of nanopore device that could help in developing fast and cheap genetic analysis. They report on a novel method that combines man-made and biological materials to result in a tiny hole on a chip, which is able to measure and analyze single DNA molecules. [Press release from Delft University of Technology discussing online prepublication in Nature Nanotechnology]
Scientists Home In on Chemicals Needed to Reprogram Cells
Scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as nerve, heart, and liver cells. [Press release from The Scripps Research Institute discussing online prepublication in Cell Stem Cell]
Scientists Discover Mechanism That Transforms Healthy Cells into Prostate Cancer
A protein that is crucial for regulating the self-renewal of normal prostate stem cells, which are needed to repair injured cells or restore normal cells killed by hormone-withdrawal therapy for cancer, also aids the transformation of healthy cells into prostate cancer cells, researchers have found. [Press release from the University of California, Los Angeles David Geffen School of Medicine discussing online prepublication in Cell Stem Cell]
Study Shows That Blood Stem Cells Are Influenced by Their Offspring
A new study has shown that mature blood cells can communicate with, and influence the behavior of, their stem cell ‘parents’. [Press release from the Walter and Eliza Hall Institute discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

New Function of Gene in Promoting Cancer Found by Researchers
Researchers have discovered that a gene well known for its involvement in tumor cell development, growth and metastasis also protects cancer cells from being destroyed by chemotherapy. [Press release from Virginia Commonwealth University discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Tiny RNA Shown to Cause Multiple Types of Leukemia
Researchers have shown in mouse models that overexpression of the microRNA 125b can independently cause leukemia and accelerate the disease’s progression. [Press release from the Whitehead Institute for Biomedical Research discussing online prepublication in the Proceedings of the National Academy of Sciences USA]
Taking the Lottery Out of Gene Therapy
Gene therapy should become a more exact science thanks to the discovery that it is possible to predict where a transferred gene is likely to be inserted into the recipient's DNA. [Press release New Scientist from discussing online prepublication in PLoS Computational Biology]
Breakthrough Therapies and a New Gene Target Advance the Treatment and Understanding of Hard-to-Treat Leukemias
Research presented at the 52nd Annual Meeting of the American Society of Hematology provides greater understanding of the optimal use of several BCR-ABL inhibitors for the treatment of acute lymphoblastic leukemia and chronic myeloid leukemia, and how a new gene target functions for several myeloid malignancies. [American Society of Hematology Press Release]
Studies Highlight Important Role of Stem Cell Transplant Procedures for the Treatment of Blood Cancers
Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. [American Society of Hematology Press Release]
Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and University College London to correct the inherited bleeding disorder. [Press release from EurekAlert! discussing research presented at the 52nd Annual Meeting of the American Society of Hematology]

Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited announced positive results from the pivotal trial of single-agent brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. [Press release from Seattle Genetics, Inc. discussing research presented at the 52nd Annual Meeting of the American Society of Hematology]
Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data
Generex Biotechnology Corporation announced two presentations of data obtained from its on-going Phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients. [Press release from Generex Biotechnology Corporation discussing research to be presented at the 33rd Annual San Antonio Breast Cancer Symposium]
Experimental Vaccine Sets Sights on Lung Cancer
An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial. [Weill Cornell Medical College Press Release]
New Brain Tumor Vaccine to Be Tested in Humans
For patients with low-grade gliomas, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. [Wake Forest University Baptist Medical Center Press Release]
Positive Results for Ark's Pre-Clinical Product Candidate EG013 in the Treatment of Fetal Growth Restriction
Ark Therapeutics Group plc announced very promising results from a number of collaborative research programs for the use of Ark's EG013, its adenoviral vector containing a vascular endothelial growth factor gene in the treatment of fetal growth restriction during pregnancy. [Ark Therapeutics Group plc Press Release]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Stage-Specific Sensitivity to p53 Restoration During Lung Cancer Progression
Data suggest that restoration of pathways important in tumor progression, as opposed to initiation, may lead to incomplete tumor regression due to the stage-heterogeneity of tumor cell populations. [Nature]
Rewiring of Genetic Networks in Response to DNA Damage
Using an approach called differential epistasis mapping, researchers have discovered widespread changes in genetic interaction among yeast kinases, phosphatases, and transcription factors as the cell responds to DNA damage. [Science]
Hybrid Pore Formation by Directed Insertion of Alpha Hemolysin into Solid-State Nanopores
Both biological pores and solid-state nanopores have significant limitations: alpha hemolysin (alpha-HL) is difficult to integrate because it relies on delicate lipid bilayers for mechanical support, and the fabrication of solid-state nanopores with precise dimensions remains challenging. Here researchers show that these limitations may be overcome by inserting a single alpha-HL pore into a solid-state nanopore. [Nat Nanotechnol]
Reprogramming of Human Primary Somatic Cells by OCT4 and Chemical Compounds
Researchers report a small molecule cocktail that enables reprogramming of human primary somatic cells to induced pluripotent stem cells with exogenous expression of only OCT4. [Cell Stem Cell]

Bmi-1 Is a Crucial Regulator of Prostate Stem Cell Self-Renewal and Malignant Transformation
Researchers conclude that Bmi-1 is a crucial regulator of self-renewal in adult prostate cells and plays important roles in prostate cancer initiation and progression. [Cell Stem Cell]

Regulation of Hematopoietic Stem Cells by Their Mature Progeny
Researchers demonstrate that the megakaryocytosis and increased platelet mass in mice with mutations in the Myb or p300 genes causes reduced circulating thrombopoietin (TPO) concentration and TPO starvation of the stem cell compartment, which is exacerbated because these cells additionally exhibit impaired responsiveness to TPO. [Proc Natl Acad Sci U S A]
Astrocyte Elevated Gene-1 Induces Protective Autophagy
The present study reveals a previously unknown aspect of AEG-1 function by identifying it as a potential regulator of protective autophagy, an important feature of AEG-1 that may contribute to its tumor-promoting properties. [Proc Natl Acad Sci U S A]

MicroRNA miR-125b Causes Leukemia
Researchers show that overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model. [Proc Natl Acad Sci U S A]
Deciphering the Code for Retroviral Integration Target Site Selection
Researchers describe a supermarker that identifies chromosomal features highly favored for retroviral integration, provides clues to the mechanism by which retrovirus integration sites are selected, and offers a tool for predicting cell-type specific proto-oncogene activation by retroviruses. [PLoS Comput Biol]



NHS Blood and Transplant and Anthony Nolan Welcome Publication of Stem Cell Strategy Report
NHS Blood and Transplant and charity Anthony Nolan welcomed the publication of a new report setting out recommendations to save 200 patient lives a year by improving the availability and quality of stem cell transplants in the UK. [National Health Service, United Kingdom]

Guidance on Institutional Review Board Continuing Review of Research (FR Doc. 2010-30198) [Department of Health and Human Services, United States]
Guidance on Institutional Review Board Approval of Research with Conditions (FR Doc. 2010-30201) [Department of Health and Human Services, United States]
Agency Information Collection Activities: Submission for OMB Review; Comment Request (FR Doc. 2010-30166) [Health Resources and Services Administration, United States]



BMTbase™ 4.1 Released
STEMSOFT Software Inc., the leading provider of software solutions for the cell therapy and transplant community, is pleased to announce the release of BMTbase 4.1. [STEMSOFT Software Inc. Press Release]

Blood Stem Cell Research to Benefit from Stem Cells Australia Initiative
The Walter and Eliza Hall Institute will partner in a newly established $32 million initiative to position Australia as an international hub for stem cell research. [Walter and Eliza Hall Institute Press Release]

Genzyme Completes Sale of Genetic Testing Business to LabCorp
Genzyme Corporation announced that it has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash. [Genzyme Corporation Press Release]

Amsterdam Molecular Therapeutics Amends Amgen GDNF Gene License Agreement
Amsterdam Molecular Therapeutics Holding N.V. announced that it has amended and restated its licensing agreement with Amgen for gene therapy applications incorporating the GDNF (glial cell derived neurotrophic factor) gene, to which Amgen holds rights. [Amsterdam Molecular Therapeutics Holding N.V. Press Release]

Tolerx and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518, a First-in-Class Anti-GITR Antibody for Cancer Treatment
Tolerx, Inc. and the Cancer Vaccine Acceleration Fund — a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research — announced they entered into a collaborative research agreement to support development of Tolerx’s drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells. [Tolerx, Inc. Press Release]

Wellcome Trust Award Could Bring Sight for Sore Eyes
A collaboration between scientists at the University of Sheffield and the LV Prasad Eye Institute in Hyderabad, India recently received an award under the new R&D for Affordable Healthcare in India scheme — a partnership between the Indian government's Department of Biotechnology and the Wellcome Trust — to support development of a stem cell-based therapy to restore sight in eyes where the cornea has been damaged by chemical injury or burns. [Wellcome Trust Press Release]

Histogen Announces Completion of Series A Financing
Histogen, Inc. announced the successful completion of its Series A financing at $10 million. [Histogen, Inc. Press Release]

NanoBio Receives $6 Million to Develop an Intranasal Vaccine for Respiratory Syncytial Virus (RSV)
NanoBio Corporation announced that it has received a $6 million grant from the Bill and Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus. [NanoBio Corporation Press Release]

State Receives $16 Million for Biomedical Research
Ten colleges and universities in the state, including the University of South Carolina, have received $16 million to support a network to develop biomedical-research programs in areas such as regenerative medicine, biochemistry and molecular biology. [University of South Carolina Press Release]

WFUBMC Orthopaedic Researchers Awarded DOD Grant
Orthopaedic researchers at Wake Forest University Baptist Medical Center (WFUBMC) have been awarded a $2.24 million four-year grant from the U. S. Department of Defense (DOD) to study the use of keratin gel in the regeneration of damaged peripheral nerves, those in the hands, arms and feet. [Wake Forest University Baptist Medical Center Press Release]

Advanced Cell Technology Files IND with FDA for First Clinical Trial Using Embryonic Stem Cells to Treat Dry AMD
Advanced Cell Technology, Inc. announced that it has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using human embryonic stem cell derived retinal pigment epithelial cells to treat patients with Dry Age-Related Macular Degeneration (AMD). [Advanced Cell Technology, Inc. Press Release]

RegeneRx Receives Australian Patent Using TB4 for Treatment of Gastrointestinal Disorders
RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (TB4) for the treatment of a broad array of gastrointestinal infections and disorders. [RegeneRx Biopharmaceuticals, Inc. Press Release]

California Stem Cell Inc. Files IND to Commence Phase I Clinical Trial in Spinal Muscular Atrophy
California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy announced that CSC has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for approval to commence a Phase I safety study on a jointly-developed stem cell-derived motor neuron transplantation therapy for Spinal Muscular Atrophy Type I. [California Stem Cell, Inc. Press Release]

Argos Therapeutics Initiates Dosing of Patients in Phase IIb Clinical Trial of Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients
Argos Therapeutics announced that it has initiated dosing of patients in a Phase IIb clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004. [Argos Therapeutics Press Release]

Alnylam's Tuschl II Patent Fully Upheld in European Opposition Proceedings
Alnylam Pharmaceuticals, Inc. announced that the European Patent Office has fully upheld its Tuschl II '044 (EP 1407044) patent in oral opposition proceedings held in Munich. [Alnylam Pharmaceuticals, Inc. Press Release]

GlaxoSmithKline and Human Genome Sciences Announce FDA Extension of Benlysta® PDUFA Target Date to 10th March 2011
GlaxoSmithKline PLC and Human Genome Sciences, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus from 9th December 2010 to 10th March 2011. [GlaxoSmithKline PLC Press Release]

The Scientist Magazine Recognizes Cellular Dynamics International’s iCell™ Cardiomyocytes Among the Winners of “Top 10 Innovations of 2010”
Cellular Dynamics International’s iCell™ Cardiomyocytes have been recognized among the top five winners of the “Top 10 Innovations of 2010” by The Scientist magazine. [Cellular Dynamics International Press Release]

Robert Klein Reacts to Nomination to Second Term as Chair of CIRM Independent Citizens' Oversight Committee
Robert N. Klein, author of Proposition 71 and Chairman of the Independent Citizens Oversight Committee, which oversees the California Institute for Regenerative Medicine (CIRM), reacted to his nomination by Governor Schwarzenegger and Lieutenant Governor Maldonado to a second term as Chair. [California Institute for Regenerative Medicine Press Release]

Growth Review Highlights Life Sciences as a Key Sector; Confirms Introduction of Patent Box and Reviews R&D Tax Credits
The government’s growth review “The path to strong, sustainable and balanced growth”, launched by the Chancellor of the Exchequer, George Osborne, is a promising road map to enable the UK to build its vibrant life sciences sector. [The Association of the British Pharmaceutical Industry Press Release]


NIH Considering New Translational Medicine Institute
Weeks after deciding to trim one of its 27 institutes and centers, the National Institutes of Health is now looking at creating a new center focused on translational medicine. [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting (FR Doc. 2010-30086)
National Cancer Institute; Notice of Meeting (FR Doc. 2010-30456)
Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-30458)
Center For Scientific Review; Notice of Closed Meetings (FR Doc. 2010-30455)

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-30082)



Updated December 14-15, 2010: Blood Products Advisory Committee Meeting Announcement

Guidance for Industry: Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application

2010 Biological License Application Supplement Noteworthy Approvals

2010 Biological Device Application Approvals 

INSTI™ HIV-1 Antibody Test



FDA and Life Sciences Industry Relationship Is Complicated by New Science and Changing Expectations, Finds PwC Survey
Growing public demand for increased medical device and drug safety, as well as the need to develop medical products faster, is complicating the current regulatory approval process and relationship between the life sciences industry and its chief regulator, the U.S. Food and Drug Administration, according to a new PricewaterhouseCoopers (PwC) report.

Reclassification of Category IIIA Biological Products, Bacterial Vaccines and Related Biological Products; Implementation of Efficacy Review; Final Order; and Delmont Laboratories, Inc.: Denial of Request for a Hearing, and Revocation of License [Docket No. FDA-2000-N-0163; Formerly Docket No. 2000N-1219]

Oncologic Drugs Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001]
Agency Information Collection Activities: Proposed Collection; Comment Request; Radioactive Drug Research Committees [Docket No. FDA-2010-N-0583]


European Medicines Agency Widens Public Access to Documents
The European Medicines Agency has published its new policy on access to documents related to medicines for human and veterinary use.


Information Sent to Healthcare Professionals in November About the Safety of Medicines


Australian Public Assessment Report (AusPAR) for Prescription Medicines
Teriparatide and Zomacton added.

Guidance for IVD Sponsors – A Roadmap to Market (Footnotes Updated)
This road map is intended for Australian sponsors of IVDs, and presents an overview of the requirements for supplying an IVD under the new regulatory framework.

National Coordinating Committee on Therapeutic Goods (NCCTG) (Updated Members)

The Regulation of Nutrigenetic Tests in Australia (Updated)

EVENTS (Listed by Date)

Genesis 2010
December 9, 2010
London, United Kingdom

Safety Symposium organized by the NIH RAC and Co-hosted by CliniGene: Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design
December 9-10, 2010
Bethesda, United States

4th International Conference on the Mechanics of Biomaterials and Tissues
December 11-14, 2010
Waikoloa, Hawaii

The American Society for Cell Biology 50th Annual Meeting
December 11-15, 2010
Philadelphia, United States

NEW The 3rd Young Investigator Stem Cell Meeting
December 14, 2010
Tel Aviv, Israel

Partnering for Cures
December 14-15, 2010
New York, United States

Pharmacology in Stem Cells Research and Regenerative Medicine
December 17, 2010
London, United Kingdom

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Functional Consequences of Structural Variation in the Genome
January 8-13, 2011
Steamboat Springs, United States

4th Annual OneMedForum
January 11-13, 2011
San Francisco, United States

COGEM Symposium: GM Viruses as Medicine: Panacea or Pandora's Box?
January 20, 2011
Amsterdam, The Netherlands

Extracellular Matrix and Cardiovascular Remodeling
January 23-28, 2011
Tahoe City, United States

5th Annual Stem Cells and Regenerative Medicine World Congress
January 24-25, 2011
San Diego, United States

BIO Asia International Partnering Conference
January 24-25, 2011
Tokyo, Japan

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Phacilitate 9th Annual North American Vaccine Forum
January 24-26, 2011
Washington, D.C., United States

IQPC’s 4th Biobanking Conference
January 24-26, 2011
Philadelphia, United States

Keystone Symposia: Stem Cells in Development, Tissue Homeostasis and Disease
January 30-February 4, 2011
Santa Fe, United States

16th Proteomics Symposium
February 3-6, 2011
Lorne, Australia

36th Lorne Conference on Protein Structure and Function
February 6-10, 2011
Lorne, Australia

CMC Workshop: Translating Science into Successful Regulatory Submissions
February 7-9, 2011
Washington, D.C., United States

Stem Cell Research Forum of India 2nd Annual Meeting
February 8-11, 2011
Bangalore, India

23rd Lorne Cancer Conference
February 10-12, 2011
Lorne, Australia

32nd Lorne Genome Conference
February 13-15, 2011
Lorne, Australia

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

1st Annual Clinical Meeting of the Cell Society
February 18-19, 2011
La Jolla, United States

SMi Stem Cells 2011 – Innovation and Commercialisation
February 23-24, 2011
London, United Kingdom

Molecular Medicine Tri-Conference: Stem Cells – Revolutionizing Regenerative Medicine and Personalized Therapy 2011
February 23-25, 2011
San Francisco, United States

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

Annual Meeting of the International Society for Cell & Gene Therapy of Cancer (ISCGT)
February 27-March 1, 2011
Doha, Qatar

9th Annual BioPartnering North America
February 27-March 1, 2011
Vancouver, Canada

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011
Boston, United States

NEW Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

6th Annual Stem Cell Summit
March 1, 2011
New York, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

Keystone Symposia: Stem Cells, Cancer and Metastasis
March 6-11, 2011
Dillon, United States

Cell Therapy Summit Europe (CTS Europe)
March 10-11, 2011
Maastricht, The Netherlands

PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

BIO-Europe Spring 2011
March 14-16, 2011
Milan, Italy

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

15th Annual Hilton Head Workshop – Regenerative Medicine, Innovations for Clinical Applications
March 16-19, 2011
Hilton Head Island, United States

HIV Evolution, Genomics and Pathogenesis
March 20-25, 2011
Whistler, Canada

StemCONN 11
March 22, 2011
Farmington, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

10th Annual New England Science Symposium
April 1, 2011
Boston, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

Clinical Gene Transfer: State of the Art Conference and e-Chips European Congress on Human iPS Cells
April 7-9, 2011
Paris, France

5th RNAi & miRNA World Congress
April 26-27, 2011
Boston, United States

3rd Epigenetics World Congress
April 26-27, 2011
Boston, United States

Inaugural Next-Gen Sequencing Congress
April 26-27, 2011
Boston, United States

GTCbio 2nd International Conference on Cancer Immunotherapy & Immunomonitoring
May 2-5, 2011
Budapest, Hungary

Australasian Gene Therapy Society (AGTS) 7th Meeting
May 4-6, 2011
Melbourne, Australia

BioPartnering India
May 4-6, 2011
Bangalore, India

NEW International Neural Transplantation and Repair 2011 (INTR11)
May 4-8, 2011
Clearwater Beach, United States

NEW World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

2nd European Biomarkers Summit
May 18-19, 2011
London, United Kingdom

Inaugural Theranostics for Personalised Medicine
May 18-19, 2011
London, United Kingdom

International Society for Cellular Therapy (ISCT) 17th Annual Meeting
May 18-21, 2011
Rotterdam, The Netherlands

American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-22, 2011
Seattle, United States

13th Annual C21 BioVentures
May 24-26, 2011
Napa, United States

Gordon Research Conference: Viruses & Cells
May 29-June 3, 2011
Lucca (Barga), Italy

NEW Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Europe 2010 Annual Conference
June 7-10, 2011
Granada, Spain

NEW 9th Annual International Cord Blood Transplantation Symposium
June 9-11, 2011
San Francisco, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News at no cost.
here to post your career opportunities.

Comments or Suggestions? Email [email protected] with your feedback.

 Learn more about Cell Therapy News:  Archives  |  Events  |  Update Profile  |  Contact Us
Subscribe  |  Unsubscribe